silibinin + ribavirin + peginterferon alfa-2b

This is a **triple combination therapy** consisting of silibinin, ribavirin, and peginterferon alfa-2b, used primarily for the treatment of chronic hepatitis C virus (HCV) infection, especially in patients who have not responded to standard dual therapy or those with post-liver transplantation reinfection. - **Silibinin** is a flavonolignan (active component of silymarin from milk thistle) with proposed antiviral and hepatoprotective activities, thought to act largely by inhibiting HCV RNA polymerase and modulating host cell functions. - **Ribavirin** is a synthetic nucleoside analogue with broad-spectrum antiviral activity, acting as a guanosine analogue to inhibit viral replication. - **Peginterferon alfa-2b** is a pegylated form of recombinant alfa interferon, an immunomodulatory protein that enhances host antiviral responses by binding to interferon receptors, leading to upregulation of antiviral genes and immune modulation. Combination of these three drugs is used experimentally to increase sustained virological response rates in difficult-to-treat HCV infections (e.g., genotype 3 post-liver transplantation, nonresponders)[1][2][5][7].